

- A prospective multicenter open-label study of 157 patients with primary open-angle glaucoma, normal tension glaucoma, or ocular hypertension undergoing prostaglandin analogues (PGA) monotherapy was performed.
- Efficacy and safety of switching to travoprost/timolol fixed-combination ophthalmic treatment (Duotrav[®], Alcon Laboratories, Inc., Fort Worth, TX, USA) was examined.
- 15.7% of patients experienced adverse events for which a relationship to Duotrav could not be ruled out.
- Switching to Duotrav in PGA monotherapy patients reduced in IOP with minimal safety concerns.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by the Japan Association of Health Service and Alcon Japan. Ltd. Medical writing assistance for this study was provided by inScience Communications. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).